Blog (insights)
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
ImmuONE featured on ITV News
Gender equality in the biotech industry has come a long way in recent years. In the UK, the US and Europe, women now make up between 40-50% of the biotech workforce, which is a higher percentage than in other STEM fields, such as engineering and the physical sciences.
From microbiology to biotech: Meet Brendon
Brendon Ghiot, our Senior Scientist at ImmuONE, joins us for a coffee to share his diverse journey from working in cellular biology to pioneering in CAR-T therapy for cancer treatment. Brendon tells us what drives his interest in developing new technologies at ImmuONE, particularly in animal-free inhalation toxicity testing.
Closing the gender gap in biotech – a Q&A with Professor Victoria Hutter, CSO of ImmuONE
Gender equality in the biotech industry has come a long way in recent years. In the UK, the US and Europe, women now make up between 40-50% of the biotech workforce, which is a higher percentage than in other STEM fields, such as engineering and the physical sciences.
That’s a wrap for 2023!
New innovations, new research, new teammates, a new lab – and soon, a new year! Before we turn our attention to 2024, let’s take a step back and appreciate all we’ve achieved so far.
Highlights from ImmuONE’s First Webinar
ImmuONE made a significant stride on November 8th by hosting its first-ever webinar, ‘unveiling insights into the next generation of tools for inhalation risk assessment’. The webinar began with a glimpse into ImmuONE's evolution, emphasizing key milestones and leadership perspectives, presented by Prof. Victoria Hutter.
Joining ImmuONE: Insights from Jo
In our most recent coffee chat, we caught up with Jo Kelsall, our new lead commercial scientist. Jo shared with us her unique career spanning the realms of science and law while also giving us the inside scoop on what life has been like so far at ImmuONE!
Scientists raise £2m for 3D human lung model to replace animal testing
Dr Abigail Martin and Professor Victoria Hutter have secured backing from the MEIF Proof of Concept & Early Stage Fund, which is managed by Mercia Ventures and part of the Midlands Engine Investment Fund (MEIF), Mercia’s EIS funds and Pioneer Group.
A coffee with Rhamiya: Being an application scientist
In our latest coffee chat, we had the pleasure of sitting down with Rhamiya Mahendran, an Application Scientist at ImmuONE...
Why in vitro methods are the future of risk assessments for inhaled substances
Inhaled substances are primarily tested on rats for toxicity, but key differences between rat and human lungs suggest it’s time to look towards alternative methods.
Reliable, reproducible, robust: morph_ONE for high content image analysis of the lung
morph_ONE is a reproducible, mechanistic-driven assay that reveals how inhaled substances affect more than a dozen morphological and biochemical features of alveolar macrophages. The assay helps companies and researchers to correctly interpret the response of the immune system in the lungs to inhaled chemical products, improving product development and ensuring safety as well as saving time and money.
Improving safety assessments of inhaled drugs with ImmuONE’s high content image analysis approaches
More than half of aerosol medicines under development are terminated due to safety concerns. ImmuONE’s high content imaging or cell painting assays are proven to accurately predict the safety of inhaled compounds by quantifying mechanism-linked morphological and biochemical characteristics within cells, contributing to faster, more informed decision making in the early stages of inhaled drug development.
Rapid Fire Round with Nilab Haydare: Life at ImmuONE
Q: What attracted you to ImmuONE as a company? A: I was initially drawn to ImmuONE because of my positive experience during my final year dissertation, where I worked on cell culture skills with Dr. Victoria Hutter...